District Of Columbia is currently home to 851 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
NCT05057702
Recruiting
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relap... Read More
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
07/23/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent, Ependymoma, Ependymoma Malignant, Ependymoma of Brain
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Emerson Clinical Research Institute, Washington, District of Columbia
Conditions: Type 2 Diabetes
Register for Updates
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
NCT06691100
Recruiting
This study aims to elucidate the differences in the gut microbiome functional activity and metabolome in adult premenopausal women with distinctive fitness levels and BMIs (with obesity, w/o obesity). The specific aims are as follows: * Aim 1: To examine the effects of acute aerobic exercise at 60-70% heart rate reserve (HRRmax) for 30 minutes bout on changes in the abundance of SCFA-producing bacteria and their functional downstream metabolic activity. * Aim 2: To examine the effects of acute... Read More
Gender:
FEMALE
Ages:
Between 21 years and 40 years
Trial Updated:
07/22/2025
Locations: Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia
Conditions: Weight Management, Obesity, Exercise, Women, Gut Microbiome, Metabolome, Health, Gut Microbiota
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Breast Neoplasms
Register for Updates
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Select Advanced Solid Tumors
Register for Updates
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
NCT02954094
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Georgetown University, Washington, District of Columbia
Conditions: Hepatocellular Cancer
Register for Updates
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT02815891
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/22/2025
Locations: Medstar Georgetown Transplant Institute, Washington, District of Columbia
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
Assistance Delivery and Muscle Coordination
NCT07011173
Recruiting
The experiment will be conducted with 15 chronic stroke survivors and 15 control subjects. Subjects will perform extension movements of the index finger of their more-impaired (stroke) or nondominant (control) hand under two different assistance types: end-effector assistance and exotendon assistance. For each assistance type, unassisted movements will be performed before and after the assistance. Subjects will be randomly assigned into two groups (A and B), who will receive the assistance in a... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
07/21/2025
Locations: Catholic University of America, Washington, District of Columbia
Conditions: Stroke
Register for Updates
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
NCT06359379
Recruiting
This is a randomized, open-label, phase 2 study evaluating the safety and efficacy of oral ropidoxuridine as a radiation-sensitizing agent in patients with newly diagnosed wild-type isocitrate dehydrogenase glioblastoma with an unmethylated O6-methylguanine-DNA methyltransferase promoter, undergoing standard 60 Gy radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Glioblastoma, IDH-wildtype
Register for Updates
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
NCT05990738
Recruiting
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent chemotherapy treatment. The purpose of this study is to find the highest dose of BI 764532 that people can tolerate when taken together with a single agent chemotherapy. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants may continue... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Small Cell Lung Carcinoma (SCLC)
Register for Updates